Tobacco/Nicotine Addiction & Psilocybin Mushrooms

Scientific Overview

LYMAN
Support Centers

800 W. 8th Ave #110, Denver, CO 80204
(303) 591-1960
www.mushrooms.support

Tobacco/Nicotine Addiction & Psilocybin Mushrooms

Expanded Scientific Overview

I. Introduction

Tobacco use disorder, predominantly driven by nicotine dependence, is a chronic relapsing condition with significant public health implications. Psilocybin, a serotonergic psychedelic, has emerged as a potential treatment modality with preliminary clinical evidence supporting its efficacy in promoting smoking cessation.

II. Tobacco/Nicotine Addiction

A. Neurobiology of Nicotine Dependence

1. Nicotine is a potent agonist at nicotinic acetylcholine receptors (nAChRs), particularly 42 and 7 subtypes.
2. Activation of nAChRs in the ventral tegmental area leads to dopamine release in the nucleus accumbens.
3. Chronic exposure results in neuroadaptation, upregulation of receptor density, and altered reward processing.
4. Withdrawal symptoms stem from decreased dopaminergic activity and increased stress-response signaling (e.g., corticotropin-releasing factor).

B. Epidemiology and Public Health Impact

1. Tobacco use is responsible for more than 8 million deaths annually (WHO, 2023).
2. Secondhand smoke contributes to 1.2 million deaths globally.

3. Lifetime relapse rates for smokers exceed 80% without effective intervention.

C. Treatment Modalities

1. Pharmacotherapies: NRT, Bupropion, Varenicline

2. Psychosocial interventions: CBT, motivational interviewing, contingency management

3. Limitations: Moderate success rates; high relapse risk; poor long-term adherence

III. Psilocybin as a Therapeutic Agent

A. Pharmacodynamics

1. Psilocybin is metabolized to psilocin, a partial agonist at 5-HT2A receptors.

2. Enhances neuroplasticity, synaptogenesis, and thalamocortical connectivity.

3. Acute effects include altered perception, emotional release, and cognitive flexibility.

B. Mechanisms of Addiction Interruption

1. Recalibration of default mode network (DMN) activity reduces compulsive behavior loops.

2. Increased introspective awareness and altered valuation of previously rewarding stimuli (e.g., nicotine).

3. Modulation of amygdala-prefrontal circuits may reduce conditioned cue-reactivity.

C. Clinical Evidence

1. Johnson et al. (2014) pilot study at Johns Hopkins:

- N = 15 chronic smokers; 23 high-dose psilocybin sessions + CBT

- 80% abstinence at 6 months; 67% abstinence at 12 months

2. fMRI and EEG findings demonstrate increased brain integration and reduced craving-related activity.

IV. Safety and Contraindications

1. Generally well-tolerated in clinical settings with professional supervision.

2. Contraindicated in individuals with psychotic disorders, bipolar I disorder, or unstable cardiovascular conditions.

3. Adverse events: transient anxiety, confusion, nausea

V. Future Directions

1. Ongoing phase 2/3 trials across institutions (e.g., Yale, NYU, Usona Institute)

2. Exploration of microdosing regimens, digital phenotyping, and personalized psychedelic protocols.

3. Policy evolution toward FDA breakthrough therapy designation and clinical integration

VI. Conclusion

Psilocybin presents a mechanistically distinct, potentially transformative intervention for tobacco addiction. Integration with psychotherapeutic support may enhance outcomes beyond existing pharmacotherapies.

References

1. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2A agonist psilocybin for tobacco addiction. J Psychopharmacol. 2014;28(11):983992.

2. Carhart-Harris RL, Friston KJ. REBUS and the Anarchic Brain: Toward a unified model of the

brain action of psychedelics. Pharmacol Rev. 2019;71(3):316344.

3. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):22952303.

4. WHO Global Tobacco Epidemic Report. World Health Organization, 2023.

Lyman Support Centers | 800 W. 8th Ave #110, Denver, CO 80204 | (303) 591-1960 | www.mushrooms.support